✨ Medicines Consent Notices




3246

NEW ZEALAND GAZETTE, No. 109

21 SEPTEMBER 2006

Schedule

Product: Baraclude
Active Ingredient: Entecavir 0.05mg/mL
Dosage Form: Oral solution
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Mt Vernon Plant, Indiana, United States of America

Product: Baraclude
Active Ingredient: Entecavir 0.5mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Mt Vernon Plant, Indiana, United States of America

Product: Baraclude
Active Ingredient: Entecavir 1mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Bristol-Myers Squibb (NZ) Company
Manufacturer: Bristol-Myers Squibb Company, Mt Vernon Plant, Indiana, United States of America

Product: Brimonidine-AFT
Active Ingredient: Brimonidine tartrate 2mg/mL
Dosage Form: Eye drops, solution
New Zealand Sponsor: AFT Pharmaceuticals Limited
Manufacturer: Sterigen Inc, Upton, Quebec, Canada

Product: Carboplatin Ebewe
Active Ingredient: Carboplatin 10mg/mL
Dosage Form: Concentrate for injection
New Zealand Sponsor: Pharmaco (NZ) Limited
Manufacturer: EBEWE Pharma GmbH Nfg KG, Unterach am Attersee, Austria

Product: Octreotide
Active Ingredient: Octreotide acetate 0.05mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Mayne Pharma Limited
Manufacturer: Omega Laboratories, Montreal, Quebec, Canada

Product: Octreotide
Active Ingredient: Octreotide acetate 0.1mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Mayne Pharma Limited
Manufacturer: Omega Laboratories, Montreal, Quebec, Canada

Product: Octreotide
Active Ingredient: Octreotide acetate 0.5mg/mL
Dosage Form: Solution for injection
New Zealand Sponsor: Mayne Pharma Limited
Manufacturer: Omega Laboratories, Montreal, Quebec, Canada

Dated this 15th day of September 2006.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go6543

Consent to the Distribution of a Changed Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set out in the Schedule hereto:

Schedule

Product: Risperdal Quicklet
Active Ingredient: Risperidone 2mg
Dosage Form: Orally disintegrating tablet
New Zealand Sponsor: Janssen-Cilag Pty Limited
Manufacturer: Janssen Ortho LLC, Mamey Ward, Gurabo, Puerto Rico

Dated this 15th day of September 2006.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go6542



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2006, No 109


Gazette.govt.nz PDF NZ Gazette 2006, No 109





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicines

πŸ₯ Health & Social Welfare
15 September 2006
Medicines, Distribution, New Medicines, Medicines Act 1981, Baraclude, Brimonidine-AFT, Carboplatin Ebewe, Octreotide
  • DON MATHESON, Deputy Director-General, Public Health

πŸ₯ Consent to the Distribution of a Changed Medicine

πŸ₯ Health & Social Welfare
15 September 2006
Medicines, Distribution, Changed Medicine, Medicines Act 1981, Risperdal Quicklet
  • DON MATHESON, Deputy Director-General, Public Health